In vitro studies with a number of these agents have demonstrated inhibition of IGF-1R, high level of growth inhibition, survival reduction, complete pathway blockade, and xenograft tumor growth reduction [41, 50–52]. The gene discussed is IGF1R; the disease is neoplasm.